Pharmacology of Antidepressants

Depressive disorders are primarily characterized by a pervasive low mood and a significant reduction in interest or pleasure in most activities. These symptoms must persist for at least two weeks to meet diagnostic criteria. This duration and the specific combination of mood changes and anhedonia (loss of interest) are essential for identifying depressive disorders, distinguishing them from other mood or psychological conditions.

The monoamine hypothesis of depression suggests that a deficiency in certain neurotransmitters, particularly serotonin and norepinephrine, contributes to the development of depressive disorders. These neurotransmitters play crucial roles in regulating mood, emotion, and overall mental well-being. When their levels are decreased, it can lead to symptoms such as sadness, lack of motivation, and cognitive difficulties, which are characteristic of depression. This hypothesis has guided research and treatment approaches, emphasizing the importance of restoring balance in these neurotransmitter systems to alleviate depressive symptoms.

Fluoxetine is classified as a Selective Serotonin Reuptake Inhibitor (SSRI) because it primarily works by inhibiting the reuptake of serotonin in the brain, increasing its availability in the synaptic cleft. This mechanism enhances mood and alleviates symptoms of depression and anxiety. In contrast, venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI), amitriptyline is a tricyclic antidepressant, and tranylcypromine is a monoamine oxidase inhibitor (MAOI), each with different mechanisms of action.

SSRIs, or selective serotonin reuptake inhibitors, work by blocking the reabsorption of serotonin in the brain. This increases the availability of serotonin in the synaptic cleft, enhancing its action on postsynaptic receptors, particularly the 5-HT1 receptors. Activation of these receptors is linked to the therapeutic effects of SSRIs, including alleviating symptoms of depression and anxiety. By stimulating 5-HT1 receptors, SSRIs help improve mood and emotional well-being, thereby contributing to their effectiveness as antidepressants and anxiolytics.

Excess serotonin can lead to the stimulation of 5-HT3 receptors, which are located in the gastrointestinal tract and the central nervous system. When these receptors are activated, they can trigger nausea and vomiting, which are common side effects associated with selective serotonin reuptake inhibitors (SSRIs). Additionally, 5-HT3 receptor activation in the brain can contribute to headache sensations. Thus, the stimulation of these receptors is closely linked to the adverse effects experienced by patients taking SSRIs.

Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is known to inhibit certain cytochrome P-450 isoenzymes, particularly CYP2D6. This inhibition can lead to altered metabolism of various medications, including beta-blockers that are metabolized by these enzymes. As a result, fluoxetine can increase plasma levels of these beta-blockers, potentially leading to enhanced effects or side effects. Understanding this interaction is crucial for managing patient medications safely and effectively.

Tricyclic Antidepressants (TCAs) are known to cause a range of side effects due to their pharmacological properties. They exhibit antimuscarinic activity, leading to dry mouth as a common side effect. Additionally, TCAs can block peripheral α1-adrenergic receptors, resulting in orthostatic hypotension, which is a drop in blood pressure upon standing. Urinary retention is another adverse effect linked to their anticholinergic properties. While increased appetite and weight gain can occur, they are not as universally recognized as the other effects listed.

MAOIs (Monoamine Oxidase Inhibitors) are not considered first-line treatment for major depression due to their potential side effects and dietary restrictions. First-line treatments typically include SSRIs (Selective Serotonin Reuptake Inhibitors) and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), which are generally safer and better tolerated. MAOIs are usually reserved for cases where other treatments have failed or for specific types of depression, such as atypical depression, due to their risk of serious interactions with certain foods and medications.

MAOIs, or monoamine oxidase inhibitors, inhibit the enzyme responsible for breaking down monoamines, including neurotransmitters and tyramine, a compound found in certain foods. When individuals consuming MAOIs eat foods high in tyramine, such as aged cheeses, cured meats, and fermented products, tyramine levels can rise dangerously. This can lead to excessive release of norepinephrine, resulting in a hypertensive crisis, characterized by a sudden spike in blood pressure. Therefore, avoiding tyramine-rich foods is crucial for those on MAOIs to prevent serious health risks.

Bupropion is contraindicated in individuals with a history of anorexia or bulimia due to its potential to lower the seizure threshold. These eating disorders can lead to electrolyte imbalances and other physiological changes that increase the risk of seizures when bupropion is used. Therefore, prescribing this medication to patients with such a history poses significant safety concerns, making it essential to avoid its use in these cases.

Mirtazapine is an atypical antidepressant that functions primarily as an α2-adrenergic antagonist. By blocking these presynaptic receptors, mirtazapine enhances the release of norepinephrine and serotonin in the synaptic cleft. This increase in neurotransmitter availability contributes to its antidepressant effects, making it effective in treating major depressive disorder. Additionally, mirtazapine also antagonizes certain serotonin receptors, further influencing serotonin levels and enhancing its therapeutic action.

Nefazodone is an antidepressant that has been associated with a higher risk of hepatic failure compared to other options. This is due to its metabolism in the liver, which can lead to hepatotoxicity in susceptible individuals. Reports of liver injury, including cases of acute liver failure, have been documented with nefazodone use, prompting its restricted use and the requirement for liver function monitoring. In contrast, other antidepressants listed have a lower incidence of liver-related adverse effects.

Aripiprazole, Quetiapine, and Esketamine are commonly used as adjunctive treatments for Treatment-Resistant Depression (TRD). Aripiprazole is an atypical antipsychotic that can enhance the effects of antidepressants. Quetiapine, another atypical antipsychotic, has mood-stabilizing properties that can help alleviate depressive symptoms. Esketamine, a rapid-acting nasal spray, targets glutamate pathways and provides quick relief for those who have not responded to traditional antidepressants. Together, these medications can improve treatment outcomes for individuals struggling with TRD.